Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.555 +0.455 (+5.00%)
Streaming Delayed Price Updated: 2:18 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Expectations For Ocular Therapeutix's Future
Via Benzinga
Earnings Scheduled For May 5, 2025
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
Via Benzinga
A Peek at Ocular Therapeutix's Future Earnings
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock
Via Benzinga
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results. 
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts
Via Benzinga
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
What 4 Analyst Ratings Have To Say About Ocular Therapeutix
Via Benzinga
Why Ocular Therapeutix Was Bumping Higher This Week
Via The Motley Fool
Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales. 
Via Benzinga
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026. 
Via Stocktwits
Earnings Scheduled For March 3, 2025
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
3 Biotech Stocks to Sell in August Before They Crash & Burn
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. 
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024
OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.